Medication
Janumet
DIN 02333872 · Merck Canada Inc
What it is
- Active ingredients
- Sitagliptin — 50 mg
- Metformin Hydrochloride — 1000 mg
- Form and route
- Tablet · Oral
- Schedule
- PRESCRIPTION
- Authorised since
- 2009-10-08
Source: Health Canada — Drug Product Database. Data current as of 2026-08-12.
Products with the same active ingredient
- Janumet XR
- Apo-Sitagliptin-Metformin
- Sandoz Sitagliptin-Metformin
- Apo-Sitagliptin/metformin XR
- Apo-Sitagliptin Malate / Metformin Hydrochloride
- Teva-Sitagliptin Malate / Metformin
- Sandoz Sitagliptin-Metformin XR
- Sitagliptin-Metformin
- Reddy-Sitagliptin and Metformin Hydrochloride
- Auro-Sitagliptin Hydrochloride and Metformin Hydrochloride
- PRZ-Sitagliptin-Metformin
- Jamp Sitagliptin Hydrochloride / Metformin
- AG-Sitagliptin Hydrochloride / Metformin
- Sitagliptin/metformin
Grouped by Health Canada’s active-ingredient group number. Products in a group do not always share a strength — check the strength above against your own. Sharing an active ingredient does not mean two products can be substituted for each other: whether a substitution is permitted is a provincial decision, and this page does not show it. Ask a pharmacist.
Ontario Drug Benefit coverage
As of 31 July 2026General benefit Part III-A
Ontario lists this product as a general benefit under the Ontario Drug Benefit program — Part III-A of the Formulary/CDI. For someone eligible for ODB, it is covered without a drug-specific approval.
- What ODB pays per unit
- $0.4446
This is what the Ontario Drug Benefit program reimburses a pharmacy for one unit, as of 31 July 2026. A deductible and a co-payment sit on top of it and differ by program — ODB, the Trillium Drug Program and the seniors co-payment each work differently — so it is not the figure anyone is charged at a counter. It also says nothing about private, workplace or federal coverage.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
Products Ontario considers interchangeable
As of 31 July 2026Ontario groups these products together at 50mg & 1000mg Tab and will substitute one for another at a pharmacy counter in Ontario.
- Apo-Sitagliptin Malate / Metformin Hydrochloride 02509431Apotex Inc
- Apo-Sitagliptin-Metformin 02435799Apotex Inc
- Auro-Sitagliptin Hydrochloride and Metformin Hydrochloride 02547821Auro Pharma Inc
- Jamp Sitagliptin Hydrochloride / Metformin 02556200Jamp Pharma Corporation
- Reddy-Sitagliptin and Metformin Hydrochloride 02540134DR Reddy's Laboratories Ltd
- Sandoz Sitagliptin-Metformin 02503972Sandoz Canada Incorporated
- Sitagliptin-Metformin 02529173Sivem Pharmaceuticals ULC
- Sitagliptin/metformin 02560461Sanis Health Inc
- Teva-Sitagliptin Malate / Metformin 02520516Teva Canada Limited
This is Ontario’s designation, under the Ontario Drug Benefit program, and it applies in Ontario. It is a different statement from the same-active-ingredient list above, which is Health Canada’s grouping and carries no substitution meaning at all. No other province’s rules are shown on this page, and a designation here is not a recommendation to switch — that is a conversation with a pharmacist or prescriber.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
How it is classified
- Anatomical main group
- Alimentary tract and metabolism
- ATC code
- A10BD07
The Anatomical Therapeutic Chemical code records the body system a medicine acts on and its chemical grouping. It is not a statement of what this medication treats, and nothing on this page is. For the full classification of A10BD07, see the WHO ATC/DDD Index.
Recalls and safety alerts
Recall matching is not available yet.
RxMonitor does not yet match Health Canada recalls to individual products — that arrives in a later release. Nothing on this page should be read as confirming that this medication has not been recalled.